Clinical Study
Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra
Table 4
Risk factors for EPF positive score.
| | EPF Positive () (%) | EPF Negative () (%) | value |
| Male | 38 (64.4) | 166 (48.3) | 0.012* | Average age (months) | 97.7 ± 45.6 | 107.6 ± 40.5 | 0.088** | Average age at diagnosis (months) | 46.3 ± 40.0 | 59.1 ± 37.0 | 0.002* | Total exposure time to HAART (months)† | 49.1 ± 24.4 | 47.3 ± 26.0 | 0.469 | Age at HAART initiation (months)† | 55.5 ± 43.1 | 71.2 ± 37.0 | 0.003* | Current WHO stage | | | <0.0001* | I | 4 (6.8) | 47 (13.8) | | II | 5 (8.4) | 73 (21.4) | | III | 21 (35.6) | 146 (42.8) | | IV | 29 (49.2) | 75 (22.0) | | Number of HAART regimen switches† | 3 (5.67) | 18 (6.48) | 0.532 | Nonadherent† | 10 (18.87) | 84 (30.22) | 0.093** |
|
|
Statistical significance (). (). Calculated using only those patients who are on HAART (, with 53 EPF Positive/278 EPF Negative).
|